Covid-19 roundup: Pfizer licenses its pill to the Medicines Patent Pool; NYC joins states in authorizing boosters for all adults ahead of FDA
Following a similar deal forged by Merck for its Covid-19 drug molnupiravir, Pfizer on Tuesday agreed to allow the UN-backed Medicines Patent Pool to license the company’s potential treatment Paxlovid to make it more readily available in 95 low- and middle-income countries.
The agreement allows MPP to grant sub-licenses to qualified generic drug manufacturers to facilitate additional production and distribution of the investigational antiviral, which has yet to be authorized.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.